onc Videos

Videos

Best Management Practices for a Patient With Pediatric Low-Grade Glioma

09/02/2024

Lindsey Hoffman, DO, discusses the course of treatment she would take for a patient with BRAF V600E-mutated pediatric ganglioglioma.

Lindsey Hoffman, DO, discusses...

09/02/2024

Oncology

Videos

Exciting Developments in Chronic Lymphocytic Leukemia Treatment Research

08/28/2024

Matthew Davids, MD, discusses groundbreaking developments in the chronic lymphocytic leukemia treatment landscape, focusing on the latest data from the ongoing AMPLIFY and MAJIC studies.

Matthew Davids, MD, discusses...

08/28/2024

Oncology

Videos

Acalabrutinib-Based Regimens Demonstrate Long-Term Benefits Among Higher-Risk Patients With CLL

08/28/2024

Matthew Davids, MD, discusses results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk chronic lymphocytic leukemia in treatment-naive or...

Matthew Davids, MD, discusses...

08/28/2024

Oncology

Videos

Best Management Practices for a Patient With Early-Stage Non-Small Cell Lung Cancer

08/28/2024

Sandip Patel, MD, University of California, San Diego, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.

Sandip Patel, MD, University of...

08/28/2024

Oncology

Videos

Insights into the FDA Approval of Denileukin Diftitox for R/R Cutaneous T-Cell Lymphoma Treatment

08/27/2024

Myron Czuczman, MD, discusses Pivotal Study 302, which led to the FDA approval of denileukin diftitox for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma.

Myron Czuczman, MD, discusses...

08/27/2024

Oncology

Kathleen Moore, MD, Stephenson Cancer Center

Videos

Treatment Landscape for Advanced/Recurrent Endometrial Cancer

08/26/2024

Kathleen Moore , MD;

Kathleen Moore, MD, discusses the current treatment landscape for patients with advanced and recurrent endometrial cancer, considering the recent expanded indication of dostarlimab plus chemotherapy.

Kathleen Moore, MD, discusses...

08/26/2024

Oncology

BJ Rimel, MD, Cedars-Sinai Medical Center

Videos

Significance of Dostarlimab Plus Chemotherapy Approval for Primary Advanced or Recurrent Endometrial Cancer

08/23/2024

BJ Rimel, MD, shares insights on the recent FDA approval which expanded the previous indication for dostarlimab plus carboplatin-paclitaxel for all patients with primary advanced or recurrent endometrial cancer.

BJ Rimel, MD, shares insights on...

08/23/2024

Oncology

Videos

Promising Developments in Chronic Lymphocytic Leukemia Treatment

08/20/2024

Talal Hilal, MD, discusses novel developments in the chronic lymphocytic leukemia treatment landscape, particularly a growing interest in utilizing measurable residual disease as an end point.

Talal Hilal, MD, discusses novel...

08/20/2024

Oncology

Videos

Innovative Developments in Myelofibrosis Treatment Options

08/16/2024

Prithviraj Bose, MD, discusses novel developments and future potential in myelofibrosis treatment, highlighting BET inhibitors, PIM kinase inhibitors, and phase 3 trial data on imetelstat, and luspatercept.

Prithviraj Bose, MD, discusses...

08/16/2024

Oncology

Videos

Exploring New Therapies on the Horizon for Patients With R/R Chronic Lymphocytic Leukemia

08/09/2024

Nirav R. Shah , MD;

Nirav Shah, MD, shares insights into the research on exciting new therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK degraders and cell therapies.

Nirav Shah, MD, shares insights...

08/09/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology